|
|
|
|
|
20.11.25 - 17:03
|
Group1 and Michigan Potash & Salt Company Announce Strategic Collaboration to Build America′s Potassium-to-Battery Supply Chain (PR Newswire)
|
|
|
AUSTIN, Texas and EVART, Mich., Nov. 20, 2025 /PRNewswire/ -- Group1, Inc., a leader in potassium-ion battery (KIB) technology, and Michigan Potash & Salt Company, LLC (MPSC), developer of the United States' largest potash and salt production facility, today announced the signing of a......
|
|
|
|
|
|
|
|
|
|
|
05.11.25 - 21:30
|
Ocumetics Reports Continued Improvement in First Group of Patients. Early Vision Results Surpass Expectations (The Newswire)
|
|
|
Calgary, Alberta – TheNewswire - November 5, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).
Ocumetics completed Group 1 surgeries in August 2025 (“Day 1”) and completed additional Group 1 surgeries in September 2025 (“Day 2”). All Group 1 patients (Day 1 and Day 2) have now completed their one-month postoperative exams, showing Corrected Distance Visual Acuity (CDVA) ranging from 20/32 to 20/25.
Click Image To View Full Size
“We are thrilled by the visual outcomes we're seeing in our first group of patients,” said Dean Burns, President and CEO of Ocumetics. “These results have met, and in some cases, exceeded internal expectations at this early stage of recovery. Every Group 1 ...
|
|
|
05.11.25 - 15:00
|
Ocumetics Reports Continued Improvement in First Group of Patients. Early Vision Results Surpass Expectations (The Newswire)
|
|
|
Calgary, Alberta – TheNewswire - November 5, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).
Ocumetics completed Group 1 surgeries in August 2025 (“Day 1”) and completed additional Group 1 surgeries in September 2025 (“Day 2”). All Group 1 patients (Day 1 and Day 2) have now completed their one-month postoperative exams, showing Corrected Distance Visual Acuity (CDVA) ranging from 20/32 to 20/25.
Click Image To View Full Size
“We are thrilled by the visual outcomes we're seeing in our first group of patients,” said Dean Burns, President and CEO of Ocumetics. “These results have met, and in some cases, exceeded internal expectations at this early stage of recovery. Every Group 1 ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.10.25 - 10:03
|
Group 1 Automotive Reports Third Quarter 2025 Financial Results (PR Newswire)
|
|
|
Current quarter diluted earnings per common share from continuing operations of $1.02 and current quarter adjusted diluted earnings per common share from continuing operations (a non-GAAP measure) of $10.45 Record quarterly revenues of $5.8 billion, a 10.8% increase over the comparable......
|
|
|
|
|
24.10.25 - 07:48
|
Interim Report Byggmax Group 1 January - 30 September, 2025 (Cision)
|
|
|
Byggmax continues to improve profitability
”Byggmax improved profitability compared to the previous year in the third quarter. Focus on our core offering combined with high operational excellence resulted in increased profit despite a continued cautious market. Byggmax continues the long-term work strengthening the core business to drive profitable growth.”
Karl Sandlund, President and CEO
The third quarter 2025
• Net sales amounted to SEK 1,949 M (1,965), a decrease of 0.8 percent.
• The Group's like-for-like sales decreased by 0.2 percent. Exchange rate effects had a negative...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
